Summary
Coenzyme Q10 (CoQ10) is tracked by OSMF as an investigational option for Long COVID; no regulator has approved it for this indication, and most post-viral conditions have no approved disease-modifying therapy at all. ClinicalTrials.gov lists 1 registered trial linking Coenzyme Q10 (CoQ10) to Long COVID: 1 is active or not yet recruiting. None of the registered studies carries a drug-development phase label, which is typical for behavioural, device and supplement protocols. It plans or enrolled 632 participants. Registered activity dates to 2025. The literature layer holds 4 publications for this pair: 4 curated references. Publication years run from 2025 to 2026. Items here are search-derived or curated references rather than classified trial reports; treat them as leads to read, not as graded evidence.
Long COVID / PASC is tracked on the OSMF post-viral programme alongside ME/CFS, Long COVID, POTS and MCAS. Across the programme, 423 candidate agents are logged for Long COVID, most of them preliminary; this page isolates the record for one of them.
Evidence table
| Evidence tier | C · Preliminary |
|---|---|
| Evidence score | 13.0 (trials 2.0, literature 6.0, tier 5, approved bonus 0.0) |
| Registered trials | 1 total: 0 recruiting, 1 active / not yet recruiting, 0 completed, 0 other |
| Linked publications | 4 (4 curated references) |
| Agent type | Behavioural (Behavioral / Protocol / Exercise, Supplement / Nutraceutical) |
| Development stage (any indication) | Investigational |
| Mechanism / class | Anti-inflammatory; Immunomodulatory; Metabolic / Mitochondrial; Neurological / Autonomic |
| Data sources | OSMF therapeutic agent database, ClinicalTrials.gov, PubMed |
| Also known as | Coenzyme Q10 (CoQ10) |
How the evidence score is calculated
- Each registered trial scores by status (recruiting / active / enrolling 3, completed 2.5, not yet recruiting 2, unknown 1, terminated / withdrawn / suspended 0.5) plus a phase bonus (phase 3-4 +2, phase 2 +1, phase 1 +0.5). The trial component is capped at 30.
- Each literature item scores by design (Cochrane review 5, meta-analysis 4, systematic review 3, RCT 3, clinical trial publication 2, curated reference 1.5, other PubMed record 1). The literature component is capped at 30.
- The existing evidence tier adds 15 (A / Strong), 10 (B / Moderate), 5 (C / Preliminary) or 0 (D / Anecdotal).
- Agents approved for any indication (max clinical phase 4) add 5, because an approved agent has an established safety profile that lowers the barrier to repurposing trials.
- The score ranks what has been studied, not what works. It does not read effect sizes or directions of effect.
Registered clinical trials
| NCT ID | Title | Status | Phase | Enrolment |
|---|---|---|---|---|
| NCT06597682 | Evaluating Immunomodulatory Interventions in Post-Acute Sequelae of SARS-CoV-2 InfEction Huashan Hospital · 2025 | not yet recruiting | Not applicable | 632 |
Published literature
- Curated reference (OSMF) Case Report: A case of post-viral inflammatory insomnia: observed sleep restoration associated with histamine-targeted interventions and imp2026
- Curated reference (OSMF) Gulf War Illness, Fibromyalgia, Myalgic Encephalomyelitis/Chronic Fatigue Syndrome and Long COVID Overlap in Common Symptoms and Underlying2025
- Curated reference PubMed record PMID 41009608
- Curated reference PubMed record PMID 41640426
Mechanism and notes
Recorded mechanism or class: Anti-inflammatory; Immunomodulatory; Metabolic / Mitochondrial; Neurological / Autonomic.
Clinical notes: Mitochondrial support, fatigue data in ME/CFS. 100-300mg ubiquinol. Very safe; consider with statins or low intake. Common in supportive regimens.
Safety: Very safe; mild GI upset rare. May interact with warfarin (monitor INR). Ubiquinol form preferred for absorption.
Dosing in studies: 100–300 mg/day (often 200 mg); 8–12+ weeks in fatigue studies.
Frequently asked questions
Is Coenzyme Q10 (CoQ10) approved for Long COVID?
Coenzyme Q10 (CoQ10) is tracked by OSMF as an investigational option for Long COVID; no regulator has approved it for this indication, and most post-viral conditions have no approved disease-modifying therapy at all. Approval status for the specific indication should always be confirmed with the relevant regulator and prescribing information.
Is Coenzyme Q10 (CoQ10) in clinical trials for Long COVID?
ClinicalTrials.gov lists 1 registered trial linking Coenzyme Q10 (CoQ10) to Long COVID: 1 is active or not yet recruiting. None of the registered studies carries a drug-development phase label, which is typical for behavioural, device and supplement protocols. It plans or enrolled 632 participants. Registered activity dates to 2025.
What does the evidence show for Coenzyme Q10 (CoQ10) in Long COVID?
Trials of Coenzyme Q10 (CoQ10) in Long COVID are registered but none has completed, so there is no outcome evidence from those studies yet; the record is a signal of research interest. OSMF's existing evidence tier for this pair is C (Preliminary), taken from the OSMF therapeutic agent database, which grades agents by the volume and design of condition-specific evidence rather than by effect size.
Cite this page
Data: ClinicalTrials.gov, PubMed, Open Targets, ChEMBL, DGIdb and the OSMF therapeutic agent database. Last updated 2026-10-07. Page built 2026-10-07.